Avatar for Zenflow

Innovative therapy for benign prostatic hyperplasia

Innovative therapy for benign prostatic hyperplasia

Fourteen million men in the US and over 200 million worldwide suffer from urinary obstruction related to benign prostatic hyperplasia (BPH). The majority of men will experience symptoms of this disease at some point in life. BPH, also known as prostate enlargement, leads to urinary straining, frequency, urgency, and sleep disruption. Despite the high prevalence and significant quality of life burden of BPH, established treatments are limited to drugs, which have limited effectiveness, and surgery, which carries a high risk of sexual side effects. The Spring device uses a mechanism known to relieve BPH symptoms with a unique design that enables it to avoid the complications associated with prior solution attempts. Urologists can deploy the device in a simple, office-based procedure that is faster and more painless than any existing therapy. We are targeting a $5 billion US market opportunity after 510(k) clearance and can achieve 90% gross margins at scale.
Co-founder @Zenflow, @Nurep; @Stanford Biodesign Fellow; @Y Combinator and @StartX alum; MS/BS @Stanford; Venture Partner @Pioneer Fund @FundRx
Former @FDA lead reviewer ; @Stanford Biodesign Fellow; MS from @University of Pittsburgh
Total raised


Funded over

2 rounds

Latest round

Seed (Jun 2015)

Zenflow hasn't added any jobs yet

Get notified when Zenflow posts new jobs.

See similar jobs